泼尼松、环磷酰胺联合川芎嗪注射液对系统性红斑狼疮患者免疫功能及其他相关因子水平的影响

Effect of Prednisone and Cyclophosphamide combine with Ligustrazine injection on immunologic function and other related factors in patients with systemic Lupus Erythematosus

目的:探讨在泼尼松和环磷酰胺的基础上加用川芎嗪注射液对系统性红斑狼疮(SLE)患者免疫功能及其他相关因子水平的影响。方法:选取我院诊治的70例SLE患者,随机分为对照组和观察组各35例。对照组应用泼尼松联合环磷酰胺进行治疗,观察组在对照组用药的基础上加用川芎嗪注射液静脉滴注。于治疗前后检测并比较两组免疫指标(IgG、C3、ANA)、基质金属蛋白酶(MMP-3、MMP-9、TIMP1)、趋化因子(CXCL9,CXCL10、CXCL11)以及血清IL-10、PRL、S100p、EET水平。结果:治疗前,两组免疫指标(IgG、C3、ANA)、基质金属蛋白酶(MMP-3、MMP-9、TIMP1)、趋化因子(CXCL9,CXCL10、CXCL11)以及血清IL-10、PRL、S100p、EET水平比较,差异无统计学意义(P>0.05);治疗后,两组免疫指标(IgG、C3、ANA)、基质金属蛋白酶(MMP-3、MMP-9)、趋化因子(CXCL9,CXCL10、CXCL11)以及血清IL-10、PRL、S100p、EET水平比较,差异具有统计学意义(P<0.05)。结论:对系统性红斑狼疮患者在泼尼松和环磷酰胺联合治疗的基础上加用川芎嗪注射液,不仅能够改善患者的免疫功能指标,而且能够改善基质金属蛋白酶、趋化因子以及相关血清因子水平,值得临床上研究应用。

Objective: To investigate the effect of prednisone and cyclophosphamide combine with ligustrazine injection on immunologic function and other related factors in patients with systemic lupus erythematosus (SLE). Methods: The subjects selected 70 patients with SLE who diagnosed and treated in our hospital from March 2014 to May 2018, divided into control group and observation group randomly, 35 cases in each group. The patients in the control group were treated with prednisone combined with cyclophosphamide, and the patients in the observation group was given intravenous drip of ligustrazine injection on the basis of the control group. Before and after treatment, detected and compared the immunologic indexes (IgG, C3, ANA), matrix metalloproteinases (MMP-3, MMP-9, TIMP1), chemotactic factor (CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups. Results: Before treatments, the immunologic indexes(IgG, C3, ANA), matrix metalloproteinases(MMP-3, MMP-9, TIMP1),chemotactic factor(CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups had no statistical significance( P >0.05);After treatments, the immunologic indexes(IgG, C3, ANA), matrix metalloproteinases(MMP-3, MMP-9), chemotactic factor(CXCL9, CXCL10, CXCL11) and serum levels of IL-10, PRL, S100 protein and EET between the two groups had statistical significances( P <0.05). Conclusion: Ligustrazine injection was added to SLE patients on the basis of prednisone combined with cyclophosphamide therapy, it not only could significantly improve the immunologic function of patients, but also improve the levels of matrix metalloproteinases, chemokines and related serum factors, it's worthy of clinical research and application.